Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, has named Mansuo Shannon, PhD as the company’s next Chief Scientific Officer (CSO).
First patient in AskBio Phase II gene therapy trial for congestive heart failure
Bayer’s AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure (CHF)
Bayer and its subsidiary AskBio touted early data from a small, early trial evaluating the safety of its gene therapy for Parkinson’s disease and announced plans for a Phase II study Thursday morning.
Asklepios BioPharmaceutical (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first patient has been randomized at the Ohio State University Wexner Medical Center in the Phase 1 REGENERATE MSA-101 clinical trial of AB-1005, a gene therapy being developed as a treatment for multiple system atrophy-parkinsonian type (MSA-P).
AskBio Presents Preliminary Data from Phase 1 Trial of Gene Therapy for Congestive Heart Failure (CHF) at the 2023 American Heart Association Scientific Sessions
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2023 /PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today announced that 20 company abstracts will be presented at the European Society for Gene and Cell Therapy (ESGCT) 30th Congress, which is being held in Brussels, Belgium, from October 24 to 27, 2023.
RESEARCH TRIANGLE PARK, N.C. , Aug. 3, 2023 /PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first patient has been dosed in the Phase 1 / Phase 2 LION-CS101 clinical trial of patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).1 AB-1003 (also known as LION-101) is a novel investigational FKRP gene replacement therapy.
Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will deliver 11 presentations offering insights into the research and development of adeno-associated virus (AAV) therapies for a range of diseases at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting taking place May 16–20, 2023, in Los Angeles, USA.
SAN SEBASTIAN, Spain, May 2, 2023 /PRNewswire/ -- TAAV Biomanufacturing Solutions S.L.U., a wholly owned subsidiary of Asklepios Biopharmaceuticals (AskBio) and Bayer AG, today presents a new brand that supports the company's transformation and purpose, which is to be the DNA manufacturing partner of choice for developers of recombinant adeno-associate virus (rAAV) technologies and thus become a fundamental part of the gene therapy industry.